Aggressive primary cutaneous CD30+ lymphoproliferative disorder in an organ transplant recipient in sustained complete remission with brentuximab vedotin

Int J Dermatol. 2018 Dec;57(12):e153-e155. doi: 10.1111/ijd.14214. Epub 2018 Sep 7.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Brentuximab Vedotin
  • Female
  • Humans
  • Immunoconjugates / therapeutic use*
  • Immunologic Factors / therapeutic use*
  • Immunosuppression Therapy / adverse effects
  • Kidney Transplantation
  • Lymphoma, Large-Cell, Anaplastic / drug therapy*
  • Lymphoma, Large-Cell, Anaplastic / etiology
  • Lymphoma, Large-Cell, Anaplastic / pathology*
  • Male
  • Middle Aged
  • Remission Induction
  • Transplant Recipients*
  • Young Adult

Substances

  • Immunoconjugates
  • Immunologic Factors
  • Brentuximab Vedotin

Grants and funding